Anders Karlsson leaves for a new assignment and Christina Herder is appointed acting CEO

Claus Thestrup

Claus Thestrup

CEO, HCA Capital Sweden

Idogen announced yesterday that Anders Karlsson has decided to leave the company to move on to a CEO role in another Swedish biotechnology company. He will remain in his current position until 1 September 2022; the board is now starting a process to recruit a successor. Christina Herder, who has been a board member of the company for more than five years, has been appointed acting CEO while the recruitment of a new CEO is underway. She will retain her role on the board during this time.

“It has been a privilege to lead Idogen for the past three years and I am convinced that the company’s competent board and employees will continue to deliver significant progress for the benefit of large patient groups as well as the shareholders,” says Anders Karlsson, resigning CEO of Idogen. “I am looking forward to being operationally involved in the advancement of the IDO 8 program in these exciting times, as we soon will be starting our Phase I/IIa study in the Nordic region,” says Christina Herder, incoming CEO of Idogen. 

Idogen develops tolerogenic cell therapies where the goal is to prevent an unwanted activation of the immune system. For patients with hemophilia A, one third of patients develop neutralizing antibodies to the standard treatment and render it inactive. To prevent the body’s immune system from attacking such biological drugs, Idogen has developed a patient-specific cell therapy with the intention of creating tolerance for the patient’s treatment. The goal is that the patient can thus continue with his vital treatment.

Disclaimer: HC Andersen Capital receives payment from Idogen for a Digital IR / Corporate Visibility subscription agreement.